Drug Shortage Report for TEVA-CLOPIDOGREL
Report ID | 212720 |
Drug Identification Number | 02388065 |
Brand name | TEVA-CLOPIDOGREL |
Common or Proper name | CLOPIDOGREL 300MG TAB |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | CLOPIDOGREL |
Strength(s) | 300MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | PP30 |
ATC code | B01AC |
ATC description | ANTITHROMBOTIC AGENTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2023-12-06 |
Estimated end date | 2024-07-20 |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2024-05-09 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.